The use of tacrolimus and cyclosporin in the treatment of vernal and atopic keratoconjunctivitis - a review of the literature

被引:0
|
作者
Chelminska, Marta [1 ]
机构
[1] Gdanski Uniwersytet Med, Klin Alergol Katedry Pneumonol & Alergol, Ul Debinki 7, PL-80952 Gdansk, Poland
来源
ALERGIA ASTMA IMMUNOLOGIA | 2018年 / 23卷 / 03期
关键词
tacrolimus; cyclosporine; atopic and vernal keratoconjunctivitis;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A significant increase in the incidence of eye diseases having an immunological basis, forces to seek new therapeutic solutions. In addition to long-used glucocorticosteroids, non-steroidal inflammatory drugs and antihistamines, the possibility of applying new drugs - cyclosporin, tacrolimus and pimecrolimus - has recently been reported. The most available studies concern the use of immunosuppressive drugs - tacrolimus and cyclosporin in the treatment of vernal and atopic keratoconjunctivitis. The mechanism of action of immunosuppressive drugs is to inhibit the activity of T lymphocytes, which consequently leads to the inhibition of gene transcription for such cytokines as interleukin 2, 3, 4 and 5 as well as interferon. or tumor necrosis factor.
引用
收藏
页码:133 / 136
页数:4
相关论文
共 50 条
  • [41] Short term results of topical cyclosporin A in patients with vernal keratoconjunctivitis
    Yildiz, Aykut ArsIan
    Bardak, Yavuz
    ASTIM ALLERJI IMMUNOLOJI, 2011, 9 (02): : 79 - 85
  • [42] Tear N-glycomics in vernal and atopic keratoconjunctivitis
    Messina, Angela
    Palmigiano, Angelo
    Tosto, Claudia
    Romeo, Donata Agata
    Sturiale, Luisa
    Garozzo, Domenico
    Leonardi, Andrea
    ALLERGY, 2021, 76 (08) : 2500 - 2509
  • [43] Use of Topical Cyclosporin and Tacrolimus for Recurrent Subepithelial Infiltrates after Epidemic Keratoconjunctivitis
    Kim, Na Hyun
    Jun, Roo Min
    Han, Kyung Eun
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2022, 63 (04): : 401 - 405
  • [44] The Treatment Effect of 0.1% Tacrolimus Eye Drops in Young and Elder Vernal Keratoconjunctivitis Patients
    Yokoi, Keiko
    Yokoi, Norihiko
    Ueta, Mayumi
    Sotozono, Chie
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [45] Aktuelles zur Keratoconjunctivitis vernalis und atopicaCurrent aspects of vernal and atopic keratoconjunctivitis
    Elisabeth M. Messmer
    Siegfried G. Priglinger
    Stefan Kassumeh
    Die Ophthalmologie, 2024, 121 : 173 - 179
  • [46] Eosinophil extracellular trap formation in the giant papillae of atopic keratoconjunctivitis and vernal keratoconjunctivitis
    Onoue, Miki
    Saga, Akiko
    Adachi, Keisuke
    Asada, Yosuke
    Hirakata, Toshiaki
    Iwamoto, Satoshi
    Ueki, Shigeharu
    Ebihara, Nobuyuki
    Matsuda, Akira
    ALLERGOLOGY INTERNATIONAL, 2024, 73 (01) : 177 - 179
  • [47] The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis
    Hingorani, M
    Calder, VL
    Buckley, RJ
    Lightman, S
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (02) : 392 - 399
  • [48] Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis
    A Kheirkhah
    M K Zavareh
    F Farzbod
    M Mahbod
    M J Behrouz
    Eye, 2011, 25 : 872 - 880
  • [49] The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis
    Yazu, Hiroyuki
    Shimizu, Eisuke
    Aketa, Naohiko
    Dogru, Murat
    Okada, Naoko
    Fukagawa, Kazumi
    Fujishima, Hiroshi
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 122 (04) : 387 - +
  • [50] Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis
    Kheirkhah, A.
    Zavareh, M. K.
    Farzbod, F.
    Mahbod, M.
    Behrouz, M. J.
    EYE, 2011, 25 (07) : 871 - 879